PTH and Hypocalcemia: Two weeks after denosumab administration, routine biochemical tests revealed severe hypocalcemia (serum calcium 6.2 mg/dl (1.55 mmol/L) (Table 1), with normal serum albumin levels and secondary hyperparathyroidism (PTH 332 pg/ml).